Agnès J. van de Wouw

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 413 citations · Full text

Breast Oncology, Oncology, Dual Her2 Blockade +7

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 320 citations · Full text

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd et al. · Breast Cancer Research and Treatment · 2013 · 239 citations

Breast Oncology, Medicine, Pathology +7

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd et al. · British Journal of Cancer · 2015 · 233 citations · Full text

Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992

Agnès J. van de Wouw, M.L.G. Janssen‐Heijnen, J.W.W. Coebergh et al. · European Journal of Cancer · 2002 · 219 citations

Southeast Netherlands, Epidemiology, Cancer Epidemiology +10